Skip to content
Bomb Report – Lifestyle
Author:
InnoCare Pharma
Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety
April 21, 2026
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
March 25, 2026
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China
March 15, 2026
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
March 6, 2026
←
Previous Page
1
2
3